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Conclusions: Strict HR control does not improve outcomes or
symptoms compared to lenient HR control in patients with
persistent AF.
Perspective: The AFFIRM study used the same target HRs
as the strict-control group of this study, and the target HRs
were achieved in >80% of patients. Yet in this study, ade-
quate HR control was achieved in only 67% of patients in
the strict-control group. Therefore, the study does not rule
out the possibility that successful implementation of a strict-
control strategy improves outcomes or symptoms compared
to lenient-control.  
Summary written by: Fred Morady, MD
Warfarin and Aspirin Use in Atrial Fibrillation
Among Practicing Cardiologists (From the
AFFECTS Registry)
Kowey PR, Reiffel JA, Myerburg R, et al.
Am J Cardiol 2010;105:1130–1134.
Study Question: What is the pattern of anticoagulation use in
patients with atrial fibrillation (AF) in contemporary practice?
Methods: This was an analysis of 1,461 patients (mean age 66
years) who had AF (paroxysmal in 80%) without structural
heart disease and were enrolled in a multicenter registry.
Participating cardiologists were trained in the American
College of Cardiology/American Heart Association/
European Society of Cardiology practice guidelines. Follow-
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Arrhythmias
Lenient Versus Strict Rate Control in Patients With
Atrial Fibrillation
Van Gelder CI, Groenveld HF, Crijns HJ, et al.
N Engl J Med 2010;Mar 15:[Epub ahead of print].
Study Question: Does strict heart rate (HR) control improve
outcomes in patients with persistent atrial fibrillation (AF)?
Methods: In this multicenter study, 614 patients (mean age 68
years) with persistent AF were randomized to lenient HR
control (n = 311, resting HR <110/minute) or strict HR
control (n = 303, HR <80/minute at rest and <110/minute
during moderate exercise) using beta-blockers, calcium-
channel blockers, and/or digoxin. Follow-up was every 2
weeks until HR targets were reached and at 1, 2, and 3
years. The 1° endpoint was a composite of cardiovascular
death, heart failure hospitalization, stroke, embolism, major
hemorrhage, and major arrhythmic events.
Results: The HR targets were reached in 98% of patients in
the lenient-control group and 67% of patients in the strict-
control group, and the mean HRs after dose-adjustment were
93 bpm and 76 bpm in the two groups, respectively. There
was no significant difference in the 3-year incidence of the 1°
endpoint between the lenient-control (12.9%) and strict-con-
trol (14.9%) groups. Approximately 46% in each group had
symptoms from AF at the end of the study.
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decline. After adjustment for age, sex, and race, the AMI hos-
pitalization rate declined by 5.8%/year. From 2002 to 2007,
white men experienced a 24.4% decrease in AMI hospitaliza-
tions, whereas black men experienced a smaller decline
(18.0%). Black women had a smaller decline in AMI hospital-
ization rate compared with white women (18.4% vs. 23.3%,
respectively).
Conclusions: AMI hospitalization rates fell markedly in the
Medicare fee-for-service population between 2002 and
2007. However, black men and women appeared to have
had a slower rate of decline compared with their white
counterparts.
Perspective: A contemporary national database for major med-
ical diagnosis and treatments should be one of the relatively
simple tools of the new health care system. These data should
be available upon request for clinical research regarding the
effect and cost-effectiveness of diagnostic and treatment para-
digms. This information will allow us to understand the
differences in outcome that are attributable to variables,
including gender and ethnicity, as in this study.  
Summary written by: Melvyn Rubenfire, MD
Interventional Cardiology
Duration of Dual Antiplatelet Therapy After
Implantation of Drug-Eluting Stents
Park SJ, Park DW, Kim YH, et al.
N Engl J Med 2010;Mar 15:[Epub ahead of print].
Study Question: What are the potential benefits and risks of
dual antiplatelet therapy beyond a 12-month period in
patients receiving drug-eluting stents (DES)?
Methods: In two trials, the investigators randomly assigned a
total 2,701 patients who had received DES and had been
free of major adverse cardiac or cerebrovascular events and
major bleeding for at least 12 months to receive clopidogrel
plus aspirin or aspirin alone. The primary endpoint was a
composite of myocardial infarction (MI) or death from car-
diac causes. Data from the two trials were merged for
analysis.
Results: Median follow-up was 19.2 months. Cumulative risk
of the primary outcome at 2 years was 1.8% with dual
antiplatelet therapy compared with 1.2% with aspirin
monotherapy (hazard ratio [HR], 1.65; 95% confidence
interval [CI], 0.80-3.36; p = 0.17). The individual risks of
MI, stroke, stent thrombosis, need for repeat revasculariza-
tion, major bleeding, and death from any cause did not
differ significantly between the two groups. However, in the
dual-therapy group as compared with the aspirin-alone
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up data were gathered for 1 year after enrollment. Choice of
therapy was at the treating physician’s discretion. The
CHADS2 score was determined by post-hoc record review;
a score ≥2 was considered indicative of a high risk of stroke.
Results: A rhythm-control strategy was used in 64% of patients
and a rate-control strategy in 36%. Overall, 83% received
either warfarin (64%) or aspirin (32%), with no significant
difference between the rhythm- and rate-control groups.
Among the high-risk patients, warfarin was used in 66% of
rhythm- and 73% of rate-control patients. Among the low-
risk patients (CHADS2 <2), warfarin was used in 49% of
rhythm- and 60% of rate-control patients. The combined rate
of embolism and cerebral nervous system bleeding was 0.9%.
Conclusions: Anticoagulation use in patients with AF often is
inconsistent with practice guidelines.
Perspective: Several studies have indicated that warfarin is
underused in patients with AF. The registry data in this
study demonstrate that this continues, with approximately
25-35% of high-risk patients not receiving warfarin despite
the guidelines training provided to the treating physicians.
The results emphasize the need for more effective dissemi-
nation and implementation of practice guidelines.  
Summary written by: Fred Morady, MD
General Cardiology
Recent Declines in Hospitalizations for Acute
Myocardial Infarction for Medicare Fee-for-Service
Beneficiaries: Progress and Continuing Challenges
Chen J, Normand SL, Wang Y, Drye EE, Schreiner GC, Krumholz HM.
Circulation 2010;121:1322–1328.
Study Question: Have recent efforts to reduce cardiovascular
risk had an effect on the rates of acute myocardial infarction
(AMI) in the United States in elderly patients?
Methods: Medicare fee-for-service patients hospitalized in the
United States with a principal discharge diagnosis of AMI
were identified through data from the Centers for Medicare
and Medicaid Services from 2002 to 2007, a time period
selected to reduce changes arising from the new definition of
AMI. The Medicare beneficiary denominator file was used to
determine the population at risk. AMI hospitalization rates
were calculated annually per 100,000 beneficiary-years with
Poisson regression analysis and stratified according to age,
sex, and race.
Results: The annual AMI hospitalization rate in the fee-for-
service Medicare population fell from 1,131 per 100,000
beneficiary-years in 2002 to 866 in 2007, a relative 23.4%
2%), whereas it was higher in the ZES patients at 18 months
(4% vs. 3%; p = 0.035).
Conclusions: The SES is superior to the ZES for patients
undergoing PCI in routine clinical practice.
Perspective: This trial suggests a lower rate of target lesion
revascularization with SES that is not surprising since the
SES has better anti-restenotic efficacy. The Endeavour III
trial had demonstrated a late catch-up phenomenon with the
SES, and longer-term follow-up of the SORT OUT III trial
will be needed to establish the long-term safety and efficacy of
ZES and SES.  
Summary written by: Hitinder S. Gurm, MBBS
Low Diagnostic Yield of Elective Coronary
Angiography
Patel MR, Peterson ED, Dai D, et al. 
N Engl J Med 2010;362:886–895.
Study Question: What is the diagnostic yield of coronary
angiography among patients with coronary artery disease
(CAD) in a contemporary national sample?
Methods: From January 2004 to April 2008, at 663 hospitals
in the American College of Cardiology National
Cardiovascular Data Registry, the authors identified
patients without known CAD who were undergoing elec-
tive cardiac catheterization. The patients' demographic
characteristics, risk factors, and symptoms and the results of
noninvasive testing were correlated with the presence of
obstructive CAD, defined as stenosis of 50% or more of the
diameter of the left main coronary artery, or stenosis of
70% or more of the diameter of a major epicardial vessel.
Results: A total of 398,798 patients were included. The
median age was 61 years; 52.7% were men, 26% had dia-
betes, and 69.6% had hypertension. Noninvasive testing
was performed in 83.9% of the patients. At catheterization,
149,739 patients (37.6%) had obstructive CAD. No CAD
(defined as <20% of stenosis in all vessels) was reported in
39.2% of patients. Independent predictors of obstructive
CAD included male sex, older age, presence of insulin-
dependent diabetes, and presence of dyslipidemia. Patients
with a positive result on a noninvasive test were moderately
more likely to have obstructive CAD than those who did
not undergo any testing (41.0% vs. 35.0%, p < 0.001).
Conclusions: In this study, only a minority of patients without
known coronary disease who underwent elective cardiac
catheterization had obstructive CAD.
Perspective: This study addresses only overutilization and not
underutilization of coronary angiography in appropriate
group, there was a nonsignificant increase in the composite
risk of MI, stroke, or death from any cause (p = 0.051) and
in the composite risk of MI, stroke, or death from cardiac
causes (p = 0.06).
Conclusions: Use of dual antiplatelet therapy for longer than
12 months in patients who had received DES was not sig-
nificantly more effective than aspirin monotherapy in
reducing the rate of MI or death from cardiac causes.
Perspective: It must be noted that the study had inadequate
statistical power to allow for a definitive conclusion regarding
the safety of clopidogrel discontinuation after 12 months.
Until results of additional studies addressing use of dual
antiplatelet therapy after implantation of DES are available,
clinicians should recommend dual antiplatelet therapy for at
least 12 months after implantation of DES, as supported by
the American Heart Association/American College of
Cardiology in a Science Advisory, and the Food and Drug
Administration.  
Summary written by: Debabrata Mukherjee, MD
Efficacy and Safety of Zotarolimus-Eluting and
Sirolimus-Eluting Coronary Stents in Routine
Clinical Care (SORT OUT III): A Randomised
Controlled Superiority Trial
Rasmussen K, Maeng M, Kaltoft A, et al., on behalf of the SORT
OUT III Study Group.
Lancet 2010;Mar 15:[Epub ahead of print].
Study Question: What is the safety and efficacy of the
zotarolimus-eluting stent (ZES) compared with the
sirolimus-eluting stent (SES) in patients with coronary
artery disease who are receiving routine clinical care?
Methods: The authors performed a single-blind superiority
trial comparing SES to ZES in all adult patients with
chronic stable coronary artery disease or acute coronary syn-
dromes undergoing percutaneous coronary intervention
(PCI) at five high-volume centers in Denmark. Follow-up
data were obtained from national administrative and health
care registries. The primary endpoint was a composite of
cardiac death, myocardial infarction, and target vessel revas-
cularization events within 9 months.
Results: The study randomized 1,162 patients to the ZES and
1,170 to a SES. The randomly allocated stent was implanted
in 1,589 (98%) lesions allocated to the ZES and 1,569 (97%)
lesions allocated to SES (p = 0.15). At 9 months, patients
treated with a ZES were more likely to have met the primary
endpoint (6% vs. 3%; p = 0.0002). This difference was sus-
tained at 18 months (10% vs. 5%; 2.19; p < 0.0001). There
was no difference in all-cause mortality at 9 months (2% vs.
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patients. However, it is obvious from this study that the cur-
rent strategies used to make decisions for proceeding to
coronary angiography, including clinical assessment and
noninvasive testing, need substantial modification and
improvement to increase the diagnostic yield of coronary
angiography and prevent over- or underutilization to
improve overall quality of patient care.  
Summary written by: Debabrata Mukherjee, MD
Prevention/Vascular
Prognostic Significance of Visit-to-Visit Variability,
Maximum Systolic Blood Pressure, and Episodic
Hypertension 
Rothwell PM, Howard SC, Dolan E, et al.
Lancet 2010;375:895–905.
Study Question: What is the prognostic significance of visit-to-
visit variability in blood pressure (BP), maximum BP reached,
untreated episodic hypertension, and residual variability in
treated patients?
Methods: The investigators determined the risk of stroke in
relation to visit-to-visit variability in BP (expressed as stan-
dard deviation [SD] and parameters independent of mean
BP) and maximum BP in patients with previous transient
ischemic attack (TIA; UK-TIA trial and three validation
cohorts) and in patients with treated hypertension
(ASCOT-BPLA trial). In ASCOT-BPLA, 24-hour ambu-
latory BP monitoring (ABPM) was also studied.
Results: In each TIA cohort, visit-to-visit variability in systolic
BP (SBP) was a strong predictor of subsequent stroke (e.g.,
top-decile hazard ratio [HR] for SD SBP over seven visits in
the UK-TIA trial, 6.22; 95p < 0.0001), independent of mean
SBP, but dependent on precision of measurement (top-decile
HR over 10 visits, 12.08; p < 0.0001). Maximum SBP reached
was also a strong predictor of stroke (HR for top decile over
seven visits, 15.01; p < 0.0001, after adjustment for mean
SBP). In ASCOT-BPLA, residual visit-to-visit variability in
SBP on treatment was also a strong predictor of stroke and
coronary events (e.g., top-decile HR for stroke, 3.25; p <
0.0001), independent of mean SBP in clinic or on ABPM.
Variability on ABPM was a weaker predictor, but all measures
of variability were most predictive in younger patients and at
lower values of mean SBP in every cohort.
Conclusions: Visit-to-visit variability in SBP and maximum
SBP are strong predictors of stroke, independent of mean
SBP.
Perspective: The study findings challenge the usual BP
hypothesis and may have implications for diagnosis, treat-
ment, and monitoring of patients with hypertension.
Additional research is needed to fully understand the associ-
ation between visit-to-visit variability in BP and risk of
vascular events, and large-scale pooled analyses of multiple
cohorts will be required to validate the current findings.  
Summary written by: Debabrata Mukherjee, MD
Effects of β blockers and Calcium-Channel
Blockers on Within-Individual Variability in Blood
Pressure and Risk of Stroke
Rothwell PM, Howard SC, Dolan E, et al.
Lancet Neurol 2010;Mar 12:[Epub ahead of print].
Study Question: What are the effects of beta-blockers and cal-
cium-channel blockers on variability in blood pressure (BP),
and do they explain the disparities in effect on stroke risk?
Methods: The Anglo-Scandinavian Cardiac Outcomes Trial
Blood Pressure Lowering Arm (ASCOT-BPLA) compared
amlodipine-based with atenolol-based regimens in 19,257
patients with hypertension and other vascular risk factors, and
the Medical Research Council (MRC) trial compared
atenolol-based and diuretic-based regimens versus placebo in
4,396 hypertensive patients ages 65-74 years. The investiga-
tors expressed visit-to-visit variability of BP during follow-up
in the two trials as standard deviation (SD) and as transforma-
tions uncorrelated with mean BP. For ASCOT-BPLA, they
also studied within-visit variability and variability on 24-hour
ambulatory blood pressure monitoring (ABPM).
Results: In ASCOT-BPLA, group systolic BP (SBP) SD was
lower in the amlodipine group than in the atenolol group at all
follow-up visits (p < 0.0001), mainly because of lower within-
individual visit-to-visit variability. Within-visit and ABPM
variability in SBP were also lower in the amlodipine group (all
p < 0.0001). Analysis of changes from baseline showed that
variability decreased over time in the amlodipine group and
increased in the atenolol group. The lower risk of stroke in the
amlodipine group was partly attenuated by adjusting for mean
SBP during follow-up, but by also adjusting for within-indi-
vidual SD of clinic SBP. Findings were similar for coronary
events. In the ABPM substudy, reduced variability in daytime
SBP in the amlodipine group (p < 0.0001) partly accounted
for the reduced risk of vascular events, but reduced visit-to-
visit variability in clinic SBP had a greater effect. In the MRC
trial, group SD SBP and all measures of within-individual
visit-to-visit variability in SBP were increased in the atenolol
group during initial follow-up (all p < 0.0001). Subsequent
temporal trends in variability in BP during follow-up in the
atenolol group correlated with trends in stroke risk.
Conclusions: The opposite effects of calcium-channel blockers
and beta-blockers on variability of BP account for the 
to the antihypertensive treatment occurred in 3.3% of the
intensive treatment group and 1.3% of the standard treatment
group (p < 0.001).
Conclusions: Among patients with type 2 diabetes who are at
high risk for cardiovascular events, lowering SBP to <120
mm Hg did not reduce rates of fatal or nonfatal major car-
diovascular events compared to a goal SBP of <140 mm Hg.
Perspective: This landmark study adds to our understanding of
management goals for high-risk diabetics and does not sup-
port aggressive lowering of SBP in high-risk diabetics.
However, whether a BP goal of <130 mm Hg provides sig-
nificant benefit as compared to <140 mm Hg remains
unanswered.  
Summary written by: Elizabeth A. Jackson, MD
Effect of Valsartan/Nateglinide on the Incidence of
Diabetes and Cardiovascular Events
The NAVIGATOR Study Group.
N Engl J Med 2010;Mar 14:[Epub ahead of print].
Study Question: Does use of short-acting insulin secretagogues
and/or renin-angiotensin-blockers reduce the risk of diabetes
or cardiovascular (CV) events among patients with impaired
glucose tolerance?
Methods: The NAVIGATOR study was a 2 x 2 factorial,
double-blind, randomized trial of patients with impaired
glucose tolerance and either established CV disease (CVD)
or risk factors for CVD. Patients were randomized to valsar-
tan (up to 160 mg daily) or placebo and to nateglinide (up
to 60 mg three times per day) or placebo and to valsartan
(up to 160 mg/day) or placebo. Subjects also received
lifestyle modification. Impaired fasting glucose tolerance was
defined as a fasting plasma glucose concentration between
95 mg/dl and 125 mg/dl. Participants were followed for a
median of 5.0 years, with primary outcomes being incident
diabetes and CV events.
Results: A total of 9,518 participants (mean age 63 years, 50%
female) from 40 countries were enrolled between January 2002
and January 2004: 1,674 subjects developed diabetes during
the follow-up period (36.0% in the nateglinide group and
33.9% for placebo), and 1,365 subjects experienced a CV
event (14.2% in the nateglinide group and 15.2% for placebo).
After adjustment for multiple comparisons, nateglinide did
not significantly reduce cumulative incidence of diabetes com-
pared with placebo (p = 0.05); CV outcomes also did not
differ. Approximately 10% of the study population lost 5% of
their baseline body weight. Those on placebo had lower mean
body weight and mean waist circumference compared to the
nateglinide group. Rates of adverse events did not differ. The
cumulative incidence of diabetes was 33.1% in the valsartan
disparity in observed effects on risk of stroke.
Perspective: The study suggests that patients with good con-
trol of mean BP, but a high residual variability in SBP had a
five times higher risk of stroke than those with low residual
SBP variability. Atenolol- and amlodipine-based treatment
had opposite effects on within-individual variability in BP
independent of their effects on mean BP. The reduced event
rates in the amlodipine group may possibly be explained by
effects on visit-to-visit variability in SBP. These findings
may have implications for the routine management of
hypertension, particularly the choice of medication, since
specific agents may have different effects on variability of BP
leading to differences in clinical efficacy.  
Summary written by: Debabrata Mukherjee, MD
Effects of Intensive Blood-Pressure Control in 
Type 2 Diabetes Mellitus 
The ACCORD Study Group.
N Engl J Med 2010;Mar 14:[Epub ahead of print]. 
Study Question: Does lowering systolic blood pressure (SBP)
to <120 mm Hg reduce risk for cardiovascular disease
(CVD) in patients with type 2 diabetes?
Methods: The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial was designed to examine the
effects of intensive blood glucose control and either blood
pressure or plasma lipid control on cardiovascular outcomes, in
10,251 diabetics from 77 sites in the United States and
Canada. In the ACCORD BP study, 4,733 subjects were ran-
domized to intensive therapy for a goal SBP <120 mm Hg or
standard therapy for a goal SBP of <140 mm Hg. All subjects
had type 2 diabetes and were at high risk for CVD or two
additional risk factors. The primary outcomes were nonfatal
myocardial infarction, nonfatal stroke, or cardiovascular death.
Mean follow-up was 4.7 years. Clinic visits were monthly for
the first 4 months, then every 2 months thereafter.
Results: Mean age was 62 years, with 47.7% women and 37%
having a history of CVD. After 1 year, the on-treatment SBP
was 119.3 mm Hg in the intensive therapy group and 133.5
mm Hg in the standard therapy group. The annual rate of pri-
mary outcome events was 1.8% in the intensive therapy group
and 2.09% in the standard therapy group (p = 0.20). The
annual rate of all-cause mortality was 1.28% for the intensive
therapy group and 1.19% for the standard therapy group (p =
0.55). The annual rate of stroke was 0.32% in the intensive
therapy group and 0.53% in the standard therapy group (p =
0.01). Reduced rates of nonfatal stroke were observed for the
intensive therapy group (p = 0.03). No significant differences
were noted for major CVD events (p = 0.50) and fatal or non-
fatal heart failure (p = 0.67). Serious adverse events attributed
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group and 36.8% for placebo, with a significantly reduced risk
for incidence of diabetes observed in the valsartan group (p <
0.001). No difference was observed in extended CV outcomes
or core CV outcomes.
Conclusions: Among patients with impaired glucose tolerance
and either established CVD or risk factors for CVD,
nateglinide for 5 years did not reduce the incidence of dia-
betes or CV events. Use of valsartan for 5 years did not lead
to reduction in the rate of CV events; however, a relative
reduction (14%) was observed for incidence of diabetes.
Perspective: This large study of nateglinide and valsartan for
prevention of diabetes and/or CVD was largely negative,
with no benefit observed in reduction of CV outcomes for
either drug, and a small benefit observed with valsartan in
reduction of diabetes. Use of aggressive lifestyle modifica-
tion, which has been shown to reduce these outcomes, as
opposed to nateglinide and/or valsartan, is recommended.  
Summary written by: Elizabeth A. Jackson, MD
Effects of Combination Lipid Therapy in Type 2
Diabetes Mellitus 
The ACCORD Study Group.
N Engl J Med 2010;Mar 14:[Epub ahead of print]. 
Study Question: Does combination therapy with a statin plus a
fibrate, as compared with statin monotherapy, reduce risk for
cardiovascular disease (CVD) in patients with type 2 diabetes
who are at high risk for CVD?
Methods: The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study was designed to examine the
effects of intensive blood glucose control and either blood
pressure or plasma lipid control on CV outcomes. The trial
included 10,251 diabetics from 77 sites in the United States
and Canada. In the ACCORD Lipid study, 5,518 subjects
were treated with open-label simvastatin (40 mg/day or less),
with randomization of masked fenofibrate or placebo. All
subjects had type 2 diabetes and were at high risk for CVD.
Baseline lipid criteria included having a low-density lipopro-
tein cholesterol (LDL-C) between 60 and 180 mg/dl,
high-density lipoprotein cholesterol (HDL-C) of 55 or less
for women or blacks, 50 or less for all others, and triglyc-
erides below 750 mg/dl not on lipid therapy (400 mg/dl if on
lipid-lowering therapy). Fasting lipids were measured at 4, 8,
and 12 weeks and annually thereafter. Secondary outcomes
included the combination of the primary outcomes and revas-
cularization or hospitalization for congestive heart failure.
Primary outcomes were first occurrence of nonfatal myocar-
dial infarction, nonfatal stroke, or CVD death. Mean
follow-up was 4.7 years.
Results: Subjects had a mean age of 62 years, 31% were female,
and 37% had a history of CVD. Use of statin therapy prior to
enrollment was 66%. Mean LDL-C on treatment was 81.1
mg/dl in the fibrate group, 80.0 mg/dl for placebo. Mean
HDL-C on treatment was 41.2 mg/dl in the fibrate group and
40.5 mg/dl for placebo. Annual rate of CVD events was 2.2%
in the fenofibrate plus simvastatin groups and 2.4% in for
placebo (p = 0.32). No significant differences between the two
groups were observed for the secondary outcomes (p = 0.30).
Annual rates of death were 1.5% in the fenofibrate group and
1.6% for placebo. In a subgroup analysis, men appeared to
have a benefit as opposed to women (p = 0.01 for interaction).
The investigators observed a possible interaction according to
the lipid subgroup, with a potential benefit for patients with
both high triglycerides and low HDL-C levels at baseline 
(p = 0.057 for interaction).
Conclusions: Simvastatin plus fenofibrate did not reduce non-
fatal myocardial infarction or stroke, and did not reduce
CVD mortality compared to simvastatin alone. These find-
ings do not support use of combination therapy in high-risk
patients with diabetes.
Perspective: This study provides data for clinicians treating
diabetes who are at high risk for CVD, suggesting that ther-
apy with statins should remain the core management
strategy in prevention of CV events. However, the subgroup
analysis warrants further evaluation; given the difference
observed in benefits related to gender, statins without fibrate
may be the treatment strategy of choice.  
Summary written by: Elizabeth A. Jackson, MD
Statins for the Primary Prevention of Cardiovascular
Events in Women With Elevated High-Sensitivity 
C-Reactive Protein or Dyslipidemia: Results From
the Justification for the Use of Statins in
Prevention: An Intervention Trial Evaluating
Rosuvastatin (JUPITER) and Meta-Analysis of
Women From Primary Prevention Trials
Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM.
Circulation 2010;121:1069–1077.
Study Question: Is statin therapy effective for primary preven-
tion of cardiovascular disease (CVD) in women?
Methods: Data from the JUPITER study were used for this
analysis. A total of 6,801 women ≥60 years, and 11,001 men
≥50 years were included. All participants had a C-reactive pro-
tein level ≥2 mg/L and a low-density lipoprotein cholesterol
<130 mg/dl. Subjects were randomized to rosuvastatin or
placebo and followed for a median of 1.9 years. A meta-analy-
sis of randomized placebo-controlled trials using statins for
primary prevention among women was performed to examine
additional trials, including JUPITER. A total of 20,147
women, mean age 60-69 years, were included in the meta-
analysis.
Results: Absolute CVD event rates, per 100 person-years in
JUPITER, were 0.57 for women randomized to rosuvastatin
and 1.04 for women on placebo, and 0.88 for men random-
ized to rosuvastatin and 1.54 for men on placebo. The relative
risk (RR) reduction was 0.54 for women and 0.58 for men.
There was a significant reduction in revascularization/unstable
angina and nonsignificant reductions in secondary events such
as myocardial infarction, stroke, and death. In the meta-analy-
sis of 13,154 women, a significant reduction in primary CVD
events was observed with statins (RR, 0.63) and a nonsignifi-
cant reduction in total mortality (RR, 0.78).
Conclusions: Data from the JUPITER trial suggest that
statins reduce primary CVD events among women, with a
relative risk similar to men. Further data from a meta-analy-
sis supported this conclusion.
Perspective: These data support the use of statins in primary
prevention of CVD events among women, particularly those
ages ≥60. Identification of long-term risk in women will assist
clinicians in identifying women who will receive the greatest
primary risk reduction from statin therapy.  
Summary written by: Elizabeth A. Jackson, MD 
Alcohol Consumption, Weight Gain, and Risk of
Becoming Overweight in Middle-Aged and 
Older Women
Wang L, Lee IM, Manson JE, Buring JE, Sesso HD.
Arch Intern Med 2010;170:453–461.
Study Question: Does regular alcohol consumption increase
weight gain among middle-age and older women?
Methods: Data from the Women’s Health Study (WHS) were
used for the analysis. US women ages 38.9 years or older, with
no cardiovascular disease, cancer, or diabetes at baseline, and
who were normal weight (body mass index [BMI] 18.5 to <25
at baseline) were included. Women were asked how often they
consumed alcoholic beverages. Body weight was reported at
baseline and via eight annual follow-up questionnaires.
Results: A total of 19,200 women were included. Over the
12.9 years of follow-up, 7,942 (41%) of these normal weight
women became overweight or obese, of which 732 women
(3.8%) became obese. An inverse relationship was observed
between alcohol consumption at baseline and weight gain.
After adjustment for multiple factors, the risk of becoming
overweight or obese was 0.96 for women who consumed 0
to <5 g/day of alcohol, 0.86 for 5 to <15 g/day alcohol
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intake, 0.70 for 15 to <30 g/day alcohol intake, and 0.73 for
30 g/day or more alcohol intake (p for trend of < 0.001).
These associations were similar for subgroups of age, smok-
ing status, physical activity level, and baseline BMI.
Conclusions: Compared to nondrinkers, women who regularly
consumed alcohol had a decreased risk of becoming over-
weight or obese over time.
Perspective: These data suggest that alcohol consumption is not
associated with weight gain among middle-age and older
women. However, these data do not suggest that alcohol
intake can prevent weight gain. Careful evaluation of nutri-
tional status in the context of individual patient’s goals and
medical history is key to overall health.  
Summary written by: Elizabeth A. Jackson, MD 
Parental Occurrence of Stroke and Risk of Stroke
in Their Children: The Framingham Study
Seshadri S, Beiser A, Pikula A, et al.
Circulation 2010;121:1304–1312.
Study Question: How does stroke in parents influence stroke risk
in children?
Methods: Data from the Framingham Heart Study and off-
spring study were used for this analysis. Children with no
history of stroke, who had parents with a history of stroke by
the age of 65 years and who completed their first, third, fifth,
and/or seventh study examination and were followed for up to
8 years after the baseline exam were included.
Results: A total of 3,443 offspring (53% female, mean age 48
± 14 years) were included. Over 77,534 person-years, a total
of 106 parental strokes were documented, of which 74 were
ischemic. Among the offspring, 128 strokes occurred, of
which 106 were ischemic. In multivariate analysis, parental
stroke was associated with an increased incidence of stroke in
the offspring (hazard ratio [HR], 2.79; 95% confidence inter-
val [CI], 1.68-4.66 for all stroke, and HR, 3.15; 95% CI,
1.69-5.88 for ischemic stroke) after adjustment for age, sex,
and baseline stroke risk factors. This association was observed
for both maternal and paternal stroke.
Conclusions: Occurrence of stroke in parents younger than 65
years is associated with increased risk of stroke in their chil-
dren.
Perspective: These data suggest that parental stroke at an early
age is an independent risk factor for stroke. Providers can eas-
ily obtain such information, which assists in the identification
of patients who may be at increased risk for stroke.  
Summary written by: Elizabeth A. Jackson, MD
Cardiovascular Screening in College Athletes 
With and Without Electrocardiography: 
A Cross-Sectional Study
Baggish AL, Hutter AM Jr, Wang F, et al.
Ann Intern Med 2010;152:269–275.
Study Question: For purposes of screening college athletes
before athletic participation, how do history and physical
examination alone compare with a strategy including routine
electrocardiography (ECG)?
Methods: Over a 3-year interval, 510 collegiate athletes at
Harvard University who underwent preparticipation screening
were studied. Each participant underwent routine history,
physical examination, ECG, and transthoracic echocardiogra-
phy (TTE) to detect or exclude cardiac findings relevant to
sports participation. TTE results were taken as the “gold stan-
dard” for disease presence. The performance of screening with
history and physical examination only was compared with that
of screening integrating history, examination, and ECG.
Results: Cardiac abnormalities relevant to sports participa-
tion risk were observed on TTE in 11 of 510 participants
(prevalence, 2.2%; including mitral valve prolapse [n = 3],
bicuspid aortic valve [n = 2], pulmonic stenosis [n = 1], left
ventricular [LV] hypertrophy [n = 2], LV dilation [n = 2],
and right ventricular dilation [n = 1]). Screening history and
physical examination alone detected abnormalities in 5 of
these 11 athletes. ECG detected five additional participants
with cardiac abnormalities, with overall sensitivity of 90.9%.
However, including ECG reduced the specificity of screen-
ing to 82.7% and was associated with a false-positive rate of
16.9% (vs. 5.5% for screening with history and examination
only). After further evaluation, athletic participation was
restricted in three athletes (one each with TTE findings of
pulmonic stenosis, LV hypertrophy, LV dilation).
Conclusions: Adding ECG to medical history and physical
examination improves the overall sensitivity of preparticipation
cardiovascular screening in athletes. However, this strategy is
associated with an increased rate of false-positive results when
current ECG interpretation criteria are used.
Perspective: The debate continues as to whether US amateur
athletes should undergo a mandatory screening ECG in
addition to only screening history and physical examination
(as is the long-standing US policy). On the surface, this
study appears to add weight to the argument for routine
preparticipation ECG. However, caveats abound, many of
which were discussed in an accompanying editorial (Maron
BJ, Ann Intern Med 2010;152:324–6).  
Summary written by: David S. Bach, MD
Cost-Effectiveness of Preparticipation Screening for
Prevention of Sudden Cardiac Death in Young
Athletes
Wheeler MT, Heidenreich PA, Froelicher VF, Hlatky MA, Ashley EA.
Ann Intern Med 2010;152:276–286.
Study Question: What is the cost-effectiveness of electrocar-
diography (ECG) plus cardiovascular-focused history and
physical examination compared with focused history and
physical examination alone for preparticipation screening in
young athletes?
Methods: A decision model was used to project the costs and
survival rates for US male and female athletes participating in
high school or college interscholastic sports. Assuming a single
screening evaluation in each athlete, models of no screening,
only focused history and physical examination, and focused
history and physical examination plus ECG were compared.
Rates of sudden cardiac death were extrapolated from an
Italian study (Corrado D, et al., JAMA 2006;296:1593–1601).
Results: According to the authors’ model, addition of ECG
to preparticipation screening saves 2.06 life-years per 1,000
athletes at an incremental total cost of $89 per athlete, and
yields a cost-effectiveness ratio of $42,900 per life-year saved
compared with cardiovascular-focused history and physical
exam alone. Compared with no screening, ECG plus cardio-
vascular-focused history and physical exam saves 2.6
life-years per 1,000 athletes screened and costs $199 per ath-
lete, yielding a cost-effectiveness ratio of $76,100 per
life-year saved.
Conclusions: Screening young athletes with 12-lead ECG plus
cardiovascular-focused history and physical examination may
be cost-effective.
Perspective: There are good reasons to believe that the Italian
experience does not extrapolate to the US. The high rate of
sudden cardiac death in Italian athletes is due to arrhythmo-
genic right ventricular dysplasia, occurring at rates far higher
than in the US. Perhaps as a result, the rate of sudden car-
diac death achieved with screening ECG in Italy now
matches the low rates seen in the US without ECG screen-
ing. Rather than using the low rates of sudden cardiac death
documented without ECG screening in the US, the authors
appear to have essentially assured a ‘positive’ study by using
data from different populations with different risks and dif-
ferent observed outcome.  
Summary written by: David S. Bach, MD
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